Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising From Pancreatic Cysts
Wald, Abigail I. , Spagnolo, Daniel M. , Grupillo, Maria, Lai, Yi-Tak, O’Broin-Lennon, Anne Marie, Park, Walter G. , Pfau, Patrick , Kubiliun, Nisa , Easler, Jeffrey J. , Dam, Aamir, Mok, Shaffer , Wallace, Michael B. , Kumbhari, Vivek , Marsh, Wallis, Thakkar, Shyam , Fairley, Kimberly, Bhat, Yasser M., Nasr, John , Khalid, Asif , Fasanella, Kenneth, Chennat, Jennifer, Singh, Harkirat , Sarkaria, Savreet, Slivka, Adam, Gabbert, Charles, Sawas, Tarek , Tielleman, Thomas , Vanderveldt, Hendrikus Dutch, Tavakkoli, Anna , Smith, Katelyn, Hruban, Ralph H. , Paniccia, Alessandro , Zureikat, Amer H., Lee, Kenneth K. , Ongchin, Melanie , Zeh, Herbert J. , Minter, Rebecca M., He, Jin , Wallace, Michael B , Nikiforova, Marina N. , Melan, Melissa A. , Brand, Randall E. , McGrath, Kevin , Polanco, Patricio Marcelo , DeWitt, John M. , Boone, Brian A. , Afghani, Elham , Ramrakhiani, Sanjay , Skef, Wasseem , Thiruvengadam, Nikhil Ravi , Das, Rohit Kumar , Smith, Lynette M. , Bell, Phoenix , Nikiforov, Yuri E. , Singhi, Aatur Dilip

Mayo Clinic

Annals of Surgery | May 22, 2023 | Volume: 278 | Issue: 4 | Pages: e789-e797

10.1097/sla.0000000000005904 | PMID 37212422 Get It

Objective: We report the development and validation of a combined DNA/RNA next-generation sequencing (NGS) platform to improve the evaluation of pancreatic cysts. Background and Aims: Despite a multidisciplinary approach, pancreatic cyst classification, such as a cystic precursor neoplasm, and the detection of high-grade dysplasia and early adenocarcinoma (advanced neoplasia) can be challenging. NGS of preoperative pancreatic cyst fluid improves the clinical evaluation of pancreatic cysts, but the recent identification of novel genomic alterations necessitates the creation of a comprehensive panel and the development of a genomic classifier to integrate the complex molecular results. Methods: An updated and unique 74-gene DNA/RNA-targeted NGS panel (PancreaSeq Genomic Classifier) was created to evaluate 5 classes of genomic alterations to include gene mutations (e.g., KRAS, GNAS, etc.), gene fusions and gene expression. Further, CEA mRNA (CEACAM5) was integrated into the assay using RT-qPCR. Separate multi-institutional cohorts for training (n=108) and validation (n=77) were tested, and diagnostic performance was compared to clinical, imaging, cytopathologic, and guideline data. Results: Upon creation of a genomic classifier system, PancreaSeq GC yielded a 95% sensitivity and 100% specificity for a cystic precursor neoplasm, and the sensitivity and specificity for advanced neoplasia were 82% and 100%, respectively. Associated symptoms, cyst size, duct dilatation, a mural nodule, increasing cyst size, and malignant cytopathology had lower sensitivities (41–59%) and lower specificities (56–96%) for advanced neoplasia. This test also increased the sensitivity of current pancreatic cyst guidelines (IAP/Fukuoka and AGA) by >10% and maintained their inherent specificity. Conclusions: PancreaSeq GC was not only accurate in predicting pancreatic cyst type and advanced neoplasia but also improved the sensitivity of current pancreatic cyst guidelines.
(223) Sexual Therapy: Patient-reported Barriers to Care
Jefferson, F, Ziegelmann, Matthew , Vencill, Jennifer A. , Köhler, Tobias , Collins, Calvin, Helo, Sevann

Mayo Clinic

The Journal of Sexual Medicine | May 22, 2023 | Volume: 20 | Issue: Supplement_1 | Pages: No page available

10.1093/jsxmed/qdad060.212 Get It

Abstract Introduction Sexual therapy for male sexual dysfunction has been used to help patients address a variety of sexual dysfunction-related conditions. While this intervention is frequently recommended for patients by male sexual health experts, the rate of adherence to the recommended therapy and associated factors is unknown. Objective To understand factors leading to completion of sex therapy consultations and barriers that prevent it. Methods A survey was developed by experts in the management of male sexual dysfunction and sex therapy at our institution. The survey included questions focusing on the decision to pursue sex therapy (or not), barriers or facilitating factors, patient perceptions regarding the referral, and treatment success. A retrospective chart review was performed to identify those patients who were referred for sexual therapy after undergoing evaluation for male sexual dysfunction at an academic Men’s Health urology clinic from 2017 - present. The survey was mailed out to these patients, and respondent survey data was compiled to evaluate survey responses. Results To date, 23 patients completed the survey (20% response rate). Sixty-five percent of survey respondents were ≥ 50 years of age, 87% were straight, and 71% were married. Reasons for sex therapy referral were frequently multi-factorial and included erectile dysfunction (65%, n=15), low libido (43%, n=10), ejaculatory dysfunction (39%, n=9), performance anxiety (30%, n=7), relationship problems (30%, n-7), and genital pain (14%, n=3). Seventy-eight percent of patients (n=18) felt that sex therapy consultation was a reasonable part of their treatment plans. Six (26%) patients did not attend their recommended sex therapy consultations. Reported barriers included sense of shame (n=2), embarrassment (n=2), scheduling conflicts (n=1), lack of anticipated benefits (n=1), and feeling dismissed by the referring provider (n=2). Those who attended sex therapy frequently reported the perception that referral made sense based on their symptoms (n=10, 59%) and/or a feeling of desperation to “do anything do get better” (n=11, 65%). Seventy-eight percent of patients who attended sex therapy found it helpful and would recommend it to a friend with a similar concern. Conclusions The majority of male patients who are referred to sexual therapy feel it is beneficial. However, one in four men choose not to pursue this line of treatment despite recommendations from their treating physicians. Future work is needed to address barriers to pursuing sex therapy. Disclosure No
Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants
Chen, Xuan , Meyer, Margaret, Kemppainen, Jennifer L., Horibe, Masayasu, Chandra, Shruti , Majumder, Shounak, Petersen, Gloria M. , Majumder, Shounak , Rabe, Kari G. , Majumder, Shounak , Meyer, Margaret A., Horibe, Masayasu

Mayo Clinic

JAMA Oncology | May 18, 2023 | Volume: 9 | Issue: 7 | Pages: 955

10.1001/jamaoncol.2023.0806 | PMID 37200008 Get It

ImportanceIncreased cancer risk in first-degree relatives of probands with pancreatic ductal adenocarcinoma (PDAC probands) who carry pathogenic or likely pathogenic germline variants (PGVs) in cancer syndrome–associated genes encourages cascade genetic testing. To date, unbiased risk estimates for the development of cancers on a gene-specific basis have not been assessed.ObjectiveTo quantify the risk of development of PDAC and extra-PDAC among first-degree relatives of PDAC probands who carry a PGV in 1 of 9 cancer syndrome–associated genes—ATM, BRCA1, BRCA2, PALB2, MLH1, MSH2, MSH6, PMS2, and CDKN2A.Design, Setting, and ParticipantsThis case series focused on first-degree relatives of PDAC probands carrying PGVs in specific cancer syndrome–associated genes. The cohort comprised clinic-ascertained patients enrolled in the Mayo Clinic Biospecimen Resource for Pancreas Research registry with germline genetic testing. In total, 234 PDAC probands carrying PGVs were drawn from the prospective research registry of 4562 participants who had undergone genetic testing of cancer syndrome–associated genes. Demographic and cancer-related family histories were obtained by questionnaire. The data were collected from October 1, 2000, to December 31, 2021.Main Outcomes and MeasuresFor the PDAC probands, the genetic test results of the presence of PGVs in 9 cancer syndrome–associated genes were obtained by clinical testing. Cancers (ovary, breast, uterus or endometrial, colon, malignant melanoma, and pancreas) among first-degree relatives were reported by the probands. Standardized incidence ratios (SIRs) were used to estimate cancer risks among first-degree relatives of PDAC probands carrying a PGV.ResultsIn total, 1670 first-degree relatives (mean [SD] age, 58.1 [17.8] years; 853 male [51.1%]) of 234 PDAC probands (mean [SD] age, 62.5 [10.1] years; 124 male [53.0%]; 219 [94.4%] White; 225 [98.7%] non-Hispanic or non-Latino]) were included in the study. There was a significantly increased risk of ovarian cancer in female first-degree relatives of probands who had variants in BRCA1 (SIR, 9.49; 95% CI, 3.06-22.14) and BRCA2 (SIR, 3.72; 95% CI, 1.36-8.11). Breast cancer risks were higher with BRCA2 variants (SIR, 2.62; 95% CI, 1.89-3.54). The risks of uterine or endometrial cancer (SIR, 6.53; 95% CI, 2.81-12.86) and colon cancer (SIR, 5.83; 95% CI, 3.70-8.75) were increased in first-degree relatives of probands who carried Lynch syndrome mismatch repair variants. Risk of PDAC was also increased for variants in ATM (SIR, 4.53; 95% CI, 2.69-7.16), BRCA2 (SIR, 3.45; 95% CI, 1.72-6.17), CDKN2A (SIR, 7.38; 95% CI, 3.18-14.54), and PALB2 (SIR, 5.39; 95% CI, 1.45-13.79). Melanoma risk was elevated for first-degree relatives of probands with CDKN2A variants (SIR, 7.47; 95% CI, 3.97-12.77).Conclusions and RelevanceIn this case series, the presence of PGVs in 9 cancer syndrome–associated genes in PDAC probands was found to be associated with increased risk of 6 types of cancers in first-degree relatives. These gene-specific PDAC and extra-PDAC cancer risks may provide justification for clinicians to counsel first-degree relatives about the relevance and importance of genetic cascade testing, with the goal of higher uptake of testing.
From Boring to Bravo! Using Learning Science to Create Memorable Presentations
Schwartz, Jennifer E. , Walsh, Katherine, Manochakian, Rami , Brondfield, Sam , Manochakian, Rami

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 17, 2023 | Volume: No volume available | Issue: 43 | Pages: No page available

10.1200/edbk_389392 | PMID 37196216 Get It

The practice of oncology continues to evolve over time. Educators find themselves in a position where they are no longer able to teach a topic in its entirety. Moreover, the rapid expansion of information available through research and discovery in the field of oncology makes it difficult for learners to process the constant barrage of new content. Lecturers continue to impart knowledge using didactic techniques, often trying to include as much material as possible in the time permitted. The question becomes: In the face of an impossibly large field, how can one assist learners in learning, and retaining, what is most important? The science of learning continues to develop, and we now recognize that there are ways to teach that optimally facilitate the retention and application of knowledge. By using these strategies, educators can make it easier for learners to absorb and retain key information. This article will touch upon several such techniques: cognitive load optimization, analogy, contrasting cases, elaboration, and just-in-time telling. By applying these methods to didactic presentations, educators can ensure that their lessons are heard, understood, and ultimately transformed into something unforgettable.
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms
Eads, Jennifer R. , Hálfdánarson, Þorvarður R. , Asmis, Tim, Belizzi, Andrew M, Bergsland, Emily K. , Dasari, Arvind , El‐Haddad, Ghassan , Mittra, Erik , Myrehaug, Sten , Nakakura, Eric K. , Raj, Nitya , Untch, Brian R. , Vijayvergia, Namrata , Chan, Jennifer A. , Myrehaug, Sten , Soares, Heloisa P , Untch, Brian , Halfdanarson, Thorvardur R , Dasari, Arvind N , Frumovitz, Michael , Meyer, Joshua E. , Soares, Heloisa P.

Mayo Clinic

Endocrine-Related Cancer | May 15, 2023 | Volume: 30 | Issue: 8 | Pages: No page available

10.1530/erc-22-0206 | PMID 37184955 Get It

High-grade neuroendocrine neoplasms are a rare disease entity and account for approximately 10% of all neuroendocrine neoplasms. Because of their rarity, there is an overall lack of prospectively collected data available to advise practitioners as to how best to manage these patients. As a result, best practices are largely based on expert opinion. Recently, a distinction was made between well-differentiated high-grade (G3) neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas, and with this, pathologic details, appropriate imaging practices and treatment have become more complex. In an effort to provide practitioners with the best guidance for the management of patients with high-grade neuroendocrine neoplasms of the gastrointestinal tract, pancreas, and gynecologic system, the North American Neuroendocrine Tumor Society convened a panel of experts to develop a set of recommendations and a treatment algorithm that may be used by practitioners for the care of these patients. Here, we provide consensus recommendations from the panel on pathology, imaging practices, management of localized disease, management of metastatic disease and surveillance and draw key distinctions as to the approach that should be utilized in patients with well-differentiated G3 neuroendocrine tumors vs poorly differentiated neuroendocrine carcinomas.
Heartbreaking Decisions: The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis
Adema, Jennifer L. , Ahiskali, Aileen , Hornback, Krutika Mediwala , Rivera, Christina G. , Mediwala Hornback, Krutika , Rivera, Christina G , Fida, Madiha , Stevens, Ryan W.

Mayo Clinic

Pathogens | May 12, 2023 | Volume: 12 | Issue: 5 | Pages: 703

10.3390/pathogens12050703 | PMID 37242373 Get It

Infective endocarditis (IE) is a rare but increasingly prevalent disease with high morbidity and mortality, requiring antimicrobials and at times surgical intervention. Through the decades of healthcare professionals’ experience with managing IE, certain dogmas and uncertainties have arisen around its pharmacotherapy. The introduction of new antimicrobials and novel combinations are exciting developments but also further complicate IE treatment choices. In this review, we provide and evaluate the relevant evidence focused around contemporary debates in IE treatment pharmacotherapy, including beta-lactam choice in MSSA IE, combination therapies (aminoglycosides, ceftaroline), the use of oral antimicrobials, the role of rifamycins, and long-acting lipoglycopeptides.
A Case of Confounding Back Pain
Green, C, Mbatidde, Lydia, Shah, Jehan R., Punj, Mantavya , Kasozi, Ramla N. , Maynard, Jennifer R. , Green, Cedric A

Mayo Clinic

American Journal of Case Reports | May 11, 2023 | Volume: 24 | Issue: No issue available | Pages: No page available

10.12659/ajcr.939784 | PMID 37303131 Get It

Correction: Garza-Lopez et al. Protocols for Generating Surfaces and Measuring 3D Organelle Morphology Using Amira. Cells 2022, 11, 65
Vue, Zer , Katti, Prasanna , Neikirk, Kit , Biete, Michelle , Lam, Jacob , Beasley, Heather K. , Rodman, Taylor, Christensen, Trace , Salisbury, Jeffrey L., Vang, Larry , Mungai, Margaret , AshShareef, Salma, Murray, Sandra , Shao, Jianqiang, Pereira, Renata O. , Hinton, Antentor , Katti, Prasanna , Biete, Michelle , Beasley, Heather K , Murray, Sandra A , Pereira, Renata O , Hinton, Antentor , Garza-López, Edgar , Marshall, Andrea G. , Streeter, Jennifer , Glancy, Brian , Abel, E. Dale

Mayo Clinic

Cells | May 11, 2023 | Volume: 12 | Issue: 10 | Pages: 1356

10.3390/cells12101356 | PMID 37408281 Get It

In the original publication [...]
Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness (RISE) Registry Data Review
Bartels, Christie M. , Jorge, April , Feldman, Candace H. , Zell, JoAnn, Bermas, Bonnie L. , Barber, Claire , Duarte‐García, Alí , Garg, Shivani , Haseley, Leah A., Jatwani, Shraddha , Johansson, Tracy, Limanni, Alex, Rodgers, Wendy, Santiago‐Casas, Yesenia, Suter, Lisa G., Ude, Jennifer, Aguirre, Alfredo , Li, Jing , Schmajuk, Gabriela , Bermas, Bonnie , Barber, Claire E H , Rovin, Brad H , Barnado, April , Aguirre, Alfredo , Li, Jing , Schmajuk, Gabriela , Yazdany, Jinoos , Duarte-García, Alí , Bartels, Christie M , Garg, Shivani , Rovin, Brad H. , Barnado, April , Ude, Jennifer, Yazdany, Jinoos

Mayo Clinic

Arthritis Care & Research | May 11, 2023 | Volume: 75 | Issue: 11 | Pages: 2295-2305

10.1002/acr.25143 | PMID 37165898 Get It

ObjectiveWe aimed to develop readily measurable digital quality measure statements for clinical care in systemic lupus erythematosus (SLE) using a multistep process guided by consensus methods.MethodsUsing a modified Delphi process, an American College of Rheumatology (ACR) workgroup of SLE experts reviewed all North American and European guidelines from 2000 to 2020 on treatment, monitoring, and phenotyping of patients with lupus. Workgroup members extracted quality constructs from guidelines, rated these by importance and feasibility, and generated evidence‐based quality measure statements. The ACR Rheumatology Informatics System for Effectiveness (RISE) Registry was queried for measurement data availability. In 3 consecutive Delphi sessions, a multidisciplinary Delphi panel voted on the importance and feasibility of each statement. Proposed measures with consensus on feasibility and importance were ranked to identify the top 3 measures.ResultsReview of guidelines and distillation of 57 quality constructs resulted in 15 quality measure statements. Among these, 5 met high consensus for importance and feasibility, including 2 on treatment and 3 on laboratory monitoring measures. The 3 highest‐ranked statements were recommended for further measure specification as SLE digital quality measures: 1) hydroxychloroquine use, 2) limiting glucocorticoid use >7.5 mg/day to <6 months, and 3) end‐organ monitoring of kidney function and urine protein excretion at least every 6 months.ConclusionThe Delphi process selected 3 quality measures for SLE care on hydroxychloroquine, glucocorticoid reduction, and kidney monitoring. Next, measures will undergo specification and validity testing in RISE and US rheumatology practices as the foundation for national implementation and use in quality improvement programs.image
Update on Emerging Therapies for Advanced Colorectal Cancer
Alese, Olatunji B. , Ulanja, Mark B. , Zheng-Lin, Binbin , Amankwah, Millicent, Eads, Jennifer R. , Alese, Olatunji B , Wu, Christina , Chapin, William Joseph

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 8, 2023 | Volume: No volume available | Issue: 43 | Pages: No page available

10.1200/edbk_389574 | PMID 37155942 Get It

Colorectal cancer (CRC) is the third most common malignancy worldwide. It is projected to increase by 3.2 million new cases and account for 1.6 million deaths by 2040. Mortality is largely due to limited treatment options for patients who present with advanced disease. Thus, the development of effective and tolerable therapies is crucial. Chemotherapy has been the backbone of systemic treatment of advanced CRC, but utility has been limited because of invariable resistance to therapy, narrow mechanisms of action, and unfavorable toxicity profile. Tumors that are mismatch repair-deficient have demonstrated remarkable response to immune checkpoint inhibitor therapy. However, most CRC tumors are mismatch repair-proficient and represent an unmet medical need. Although ERBB2 amplification occurs only in a few cases, it is associated with left-sided tumors and a higher incidence of brain metastasis. Numerous combinations of HER2 inhibitors have demonstrated efficacy, and antibody-drug conjugates against HER2 represent innovative strategies in this area. The KRAS protein has been classically considered undruggable. Fortunately, new agents targeting KRAS G12C mutation represent a paradigm shift in the management of affected patients and could lead the advancement in drug development for the more common KRAS mutations. Furthermore, aberrant DNA damage response is present in 15%-20% of CRCs, and emerging innovative combinations with poly (ADP-ribose) polymerase (PARP) inhibitors could improve the current therapeutic landscape. Multiple novel biomarker-driven approaches in the management of patients with advanced CRC tumors are reviewed in this article.